Study S001054

A Thorough QTc Evaluation of the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Study With a Nested Crossover Design for Positive Control With Moxifloxacin Administration

ClinicalTrials.gov record

Registration

Registration: NCT05668936
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: TERMINATED
Enrollment: 31
Start: 2023-01-03
Primary completion: 2023-03-10
Lead sponsor: AstraZeneca
Conditions: Non-alcoholic Steatohepatitis
Interventions: DRUG:Cotadutide; DRUG:Cotadutide-placebo; DRUG:Moxifloxacin; DRUG:Moxifloxacin-placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2022-002479-12

Registered primary outcomes

Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF) [Up to Day 92]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.